Bio Key International (BKYI) Cash & Equivalents (2010 - 2026)

Bio Key International has reported Cash & Equivalents for 17 years, with the latest figure at $2.2 million in Q1 2026.

• Quarterly Cash & Equivalents fell 28.27% year-over-year to $2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.2 million (down 28.27% YoY) and the FY2025 annual result came in at $2.7 million, up 515.78% from the prior year.
• Cash & Equivalents retreated to $2.2 million in Q1 2026 per BKYI's latest filing, from $2.7 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $5.8 million in Q1 2022 and troughed at $307086.0 in Q3 2023.
• A 5-year average of $2.0 million and a median of $2.0 million in 2025 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2023 and 2025: Cash & Equivalents slumped 89.03% in 2023, then soared 515.78% in 2025.
• Over 5 years, Cash & Equivalents stood at $2.6 million in 2022, then slumped by 80.6% to $511400.0 in 2023, then retreated by 14.43% to $437604.0 in 2024, then jumped by 515.78% to $2.7 million in 2025, then declined by 16.58% to $2.2 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $2.2 million, $2.7 million, and $2.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.